Evidence map›Paper›PMID 37795521›Full record

ArticleFrontiers in reproductive health2023

Evaluating the use of oral pre-exposure prophylaxis among pregnant and postpartum adolescent girls and young women in Cape Town, South Africa.

Nehaa Khadka, Pamina M Gorbach, Dorothy C Nyemba, Rufaro Mvududu, Nyiko Mashele, Marjan Javanbakht, Roch A Nianogo, Grace M Aldrovandi, Linda-Gail Bekker, Thomas J Coates and 2 more

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in reproductive health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03826199 phase4completednot on this map

Evaluation of Pre-exposure Prophylaxis Cascade in Pregnant and Breastfeeding Women in Cape Town, South Africa (Formative Study)

TypeinterventionalSponsorUniversity of California, Los AngelesRan2019 to 2023Enrolled200ConditionsHivArmsTDF-FTC, Counselling on PrEP in antenatal and postnatal care
NCT03902418 completednot on this map

Evaluation of Pre-Exposure Prophylaxis (PrEP) Initiation, Retention, and Adherence in Pregnant and Breastfeeding Women

TypeobservationalSponsorUniversity of California, Los AngelesRan2019 to 2024Enrolled1,195ConditionsHIV-I InfectionArmsemtricitabine/tenofovir
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nehaa KhadkaDepartment of Epidemiology, Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA, United States.
Pamina M GorbachDepartment of Epidemiology, Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA, United States.
Dorothy C NyembaDivision of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
Rufaro MvududuDivision of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
Nyiko MasheleDivision of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
Marjan JavanbakhtDepartment of Epidemiology, Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA, United States.
Roch A NianogoDepartment of Epidemiology, Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA, United States.
Grace M AldrovandiDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States.
Linda-Gail BekkerThe Desmond Tutu Health Foundation, University of Cape Town, Cape Town, South Africa.
Thomas J CoatesDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States.
Landon MyerDivision of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
Dvora L Joseph DaveyDepartment of Epidemiology, Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA, United States.

Funding

Evaluating the PrEP cascade in HIV-negative pregnant and breastfeeding women in South Africa (PrEP-PP)R01MH116771 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JOSEPH DAVEY, DVORA LEAH, MYER, BENJAMIN LANDON · 2018 to 2022
$2.5M
Evaluation of pre-exposure prophylaxis cascade in pregnant and breastfeeding women in Cape Town, South AfricaK01TW011187 · FIC · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JOSEPH DAVEY, DVORA LEAH · 2018 to 2022
$698k
FIC NIH HHS K01 TW011187NIMH NIH HHS R01 MH116771
6 · The paper itself

Abstract

Background: Adolescent girls and young women (AGYW) in South Africa are at a higher risk of acquiring HIV. Despite the increasing availability of daily oral pre-exposure prophylaxis (PrEP) for HIV prevention, knowledge on PrEP use during pregnancy and postpartum periods at antenatal care (ANC) facilities remains inadequate. Methods: Data from HIV-uninfected pregnant women in Cape Town, South Africa, were used in this study. These women aged 16-24 years were enrolled in the PrEP in pregnancy and postpartum (PrEP-PP) cohort study during their first ANC visit. Using the PrEP cascade framework, the outcomes of the study were PrEP initiation (prescribed tenofovir disoproxil fumarate and emtricitabine at baseline), continuation (returned for prescription), and persistence [quantifiable tenofovir diphosphate (TFV-DP) in dried blood samples]. The two primary exposures of this study were risk perception for HIV and baseline HIV risk score (0-5), which comprised condomless sex, more than one sexual partner, partner living with HIV or with unknown serostatus, laboratory-confirmed sexually transmitted infections (STIs), and hazardous alcohol use before pregnancy (Alcohol Use Disorders Identification Test for Consumption score ≥ 3). Logistic regression was used to examine the association between HIV risk and PrEP, adjusting for Results: A total of 486 pregnant women were included in the study, of which 16% were "adolescents" (aged 16-18 years) and 84% were "young women" (aged 19-24 years). The adolescents initiated ANC later than the young women [median = 28 weeks (20-34) vs. 23 weeks (16-34), Conclusions: AGYW were found to have high oral PrEP initiation, but just over one-third of these women continued PrEP use through 6 months. Pregnant AGYW who had a higher risk of acquiring HIV (due to condomless sex, frequent sex, and STIs) were more likely to continue on PrEP use through the postpartum period. Pregnant and postpartum AGYW require counseling and other types of support, such as community delivery and peer support to improve their effective PrEP use through the postpartum period. Clinical Trial Number: ClinicalTrials.gov, NCT03826199.

Indexed as

adherenceAGYWbreastfeedingcohort studiesoral pre-exposure prophylaxispregnantSouth Africa

Identifiers

PMID37795521
PMCPMC10546059

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.